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In vitro harnessing of immune cells is the most important advance in the field of cancer 
immunotherapy. Results shown in the current paper may be used to harness natural killer 
(NK) cells in vitro. It is observed that drugs used to treat multiple sclerosis such as glati-
ramer acetate, dimethyl fumarate, and monomethyl fumarate upregulate the expression 
of chemokines receptor 10 (CCR10) on the surface of human IL-2-activated NK cells. 
This is corroborated with increased chemotaxis of these cells toward the concentration 
gradients of the ligands for CCR10, namely CCL27 and CCL28. It is also demonstrated 
that these three drugs enhance NK cell cytotoxicity against tumor target cells, an activity 
that is abrogated by prior incubation of the cells with anti-CCR10 antibody. Because 
CCL27 and CCL28 are secreted by selective tumor types such as malignant melanoma, 
squamous cell carcinomas, and colorectal cancer, respectively, it is hypothesized that 
activated NK cells may be harnessed in vitro with any of these drugs before utilizing them 
as a therapeutic modality for cancer.
Keywords: nK cells, glatiramer acetate, dimethyl fumarate, monomethyl fumarate, cancer, chemotaxis, 
cytotoxicity
inTrODUcTiOn
Natural killer (NK) cells perform several important functions; among them, the regulation of the 
adaptive immune response by secreting cytokines such as IFN-γ, shaping the innate immune system 
by interacting with dendritic cells, defending against viral infection, and lysing and destroying tumor 
cells (1–5). Resting NK cells respond to dangers occurring at sites of injury. Evidence gathered from a 
mouse xenograft tumor model testing functionally deficient NK cells or antibody-mediated NK cell 
depletion supports that NK cells can eradicate tumor cells. An 11-year follow-up study in patients 
indicated that low NK-like cytotoxicity was associated with increased cancer risk (6). High levels of 
tumor-infiltrating NK cells are associated with a favorable tumor outcome in patients with colorectal 
carcinoma, gastric carcinoma, and squamous cell lung cancer, suggesting that NK cell infiltration 
into tumor tissues represents a positive prognostic marker (7).
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Chemokines are molecules that play essential roles in linking 
the innate and adaptive immune responses (8) and are crucial 
in health and diseases (9). They have low molecular weights 
and are divided into four subfamilies based on the position 
of the cysteine (C) residue in the amino terminal end of the 
molecules; these are known as CXC, CC, C, and CX3C. They 
play important roles in NK cell biology maintaining them in 
the bone marrow, guiding them into the circulation, and aiding 
their accumulation at sites of injury. The field examining the 
expression of chemokine receptors in NK cells, and their ability 
to induce their migration, started in early 1990s (10, 11). There 
are overwhelming results describing the effects of chemokines 
on various biological activities of NK cells [reviewed in 
Ref. (12)].
Glatiramer acetate (GA; commercial name Copaxone) is 
a synthetic compound made up of the four amino acids Glu, 
Ala, Lys, and Tyr that are most common in myelin basic 
protein (13). GA is a first-line immunomodulatory therapy in 
relapsing-remitting multiple sclerosis (RRMS) patients (14). 
Although the drug is not as effective as second-line therapies 
such as Natalizumab and Fingolimod, GA is widely used 
due to few serious side effects. This drug showed promise in 
maintenance therapy, when used after more intensive immu-
nosuppression (15). It was also reported that GA enhanced 
the in  vitro killing of autologous and allogeneic human 
immature and mature monocyte-derived dendritic cells (DCs) 
by activated human NK cells (16). Further, administration of 
GA into mice ameliorated the EAE clinical scores, and this 
was associated with high killing of dendritic cells by NK cells 
isolated from the same mice (17).
Dimethyl fumarate (DMF), also known as Tecfidera (Biogen, 
Cambridge, MA, USA), has been approved by the FDA as an oral 
therapy for multiple sclerosis (MS) patients due to its efficacy. 
The mechanism of action of DMF is not completely understood. 
However, it was suggested that DMF may be hydrolyzed by ester-
ases to monomethyl fumarate (MMF), although it is not yet clear 
whether MMF might mediate the in situ effects of DMF (18). It 
has also been demonstrated that DMF inhibits the proliferation 
of A375 or M24met cell lines and reduces melanoma growth and 
metastasis in experimental melanoma mouse models (19).
We recently reported that MMF increased primary human 
CD56+ NK cell lysis of K562 and RAJI tumor cells (20). Moreover, 
MMF upregulated the expression of NKp46 on the surface of 
NK cells, which was correlated with upregulation of CD107a 
(lysosomal-associated membrane protein-1 “LAMP-1”) on the 
surface of CD56+ NK cells, and the release of Granzyme B from 
CD56 NK cells (20). Moreover, MMF inhibited the EAE clini-
cal score in SJL mice correlated with enhanced NK cell lysis of 
dendritic cells (21).
In the present report, we describe a novel effect of GA, MMF, 
and DMF. We observed that these drugs upregulate the expression 
of CCR10 on the surface of IL-2-activated NK cells, corroborated 
with increased cytotoxicity, and induced chemotaxis toward the 
ligands for CCR10, namely CCL27 and CCL28. These observa-
tions may have implications for utilizing the highly antitumor 
effector NK cells in the therapy of cancer, particularly for those 
patients where tumor cells secrete the ligands for CCR10.
MaTerials anD MeThODs
reagents
FITC-conjugated mouse antihuman CCR3, CCR4, CCR5, CCR6, 
CCR7, CCR9, CXCR1, CXCR3, CXCR4, and CXCR5 or unconju-
gated monoclonal mouse-antihuman CCR1, CCR2, and CXCR6, 
as well as PE-conjugated rat antihuman CCR8, PE-conjugated 
rat antihuman CCR10, and PE-conjugated rat IgG2b, were 
obtained from R&D Systems Europe Ltd. (Abingdon, UK). 
FITC-conjugated mouse antihuman CX3CR1 was purchased 
from Medical and Biological Laboratories Co. Ltd. (Nagoya, 
Japan). FITC-conjugated monoclonal mouse antihuman CD3, 
PE-conjugated monoclonal mouse antihuman CD56, and 
FITC-conjugated goat anti-mouse were purchased from Becton-
Dickinson (San Diego, CA, USA). FITC-conjugated mouse IgG, 
PE-conjugated mouse IgG, unconjugated mouse IgG, and uncon-
jugated rat IgG were obtained from either Becton-Dickinson or 
from R&D Systems. Pertussis toxin (PTX), MMF, and DMF were 
obtained from Sigma-Aldrich (Saint Louis, MO, USA). CCL1, 
CCL27, CCL28, and CXCL10 were purchased from PeproTech 
(London, UK).
Preparation and culture of nK cells
Buffy coats from normal human volunteers were obtained from 
the blood bank (Ulleval Hospital, Oslo). Human IL-2-activated 
NK cells were prepared using Histopaque-1077 (Sigma-Aldrich) 
and RosetteSep human NK cell enrichment cocktail (Stemcell 
Technologies, SARL, Grenoble, France). NK cells were nega-
tively selected by removing cells expressing CD3, CD4, CD19, 
CD36, CD66b, CD123, and glycophorin A. More than 95% of 
these cells expressed the CD56 molecule but lacked the CD3 
molecule as determined by flow cytometric analysis (Figure S1 in 
Supplementary Material). Purified NK cells were then placed in 
flasks at 1 × 106/mL and 200 U/mL IL-2 (PeproTech, Rocky Hill, 
NJ, USA), and then incubated at 37°C in a 5% CO2 incubator for 
5–7 days.
nK cell cytotoxicity assay
The human myeloid leukemia cell line K562 cells (CCL-243 
obtained from American type culture collection “ATCC,” 
Manassas, VA, USA) or RAJI human lymphoma cells (CCL-214, 
ATCC), were used as target cells. Target cells were incubated at 
1 × 106 cells/mL with 5 μg/mL Calcein AM (Sigma-Aldrich) for 
45 min. The cells were pelleted by centrifugation and resuspended 
in RPMI. To obtain total lysis, these cells were incubated in 
96-well plates with 0.05% Triton X, whereas they were incubated 
with medium alone to obtain total viability. In other cultures, 
Calcein-AM-labeled cells were incubated at 37°C in a 5% CO2 
incubator with activated NK cells at different NK target cell ratios 
for 4 h. The plates were centrifuged, supernatants were removed, 
and replaced with PBS. Fluorescence units (FUs) were measured 
in Cytofluor plate reader. The percentage of cytotoxicity was 
calculated according to the following formula: % viability = FU 
of targets incubated with IL-2-activated NK cells (experimental) 
minus FU of targets incubated with Triton X, divided by FU of 
targets incubated in medium only (total viability), minus FU of 
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targets incubated with Triton X (total lysis). In the figures, the 
10:1 effector:target (E:T) cell ratio is shown; however, similar 
results were obtained using other E:T cell ratios (2.5:1 and 5:1). Of 
note, the media of incubation contains RPMI plus 10% FCS. For 
anti-CCR10 treatment, the cells were washed and then treated 
with 10 μg/mL anti-CCR10 or 10 μg/mL isotype control antibody 
for 45 min at 4°C, washed and examined for viability. Only more 
than 95% viable cells were then added to Calcein-AM-labeled 
target cells and incubated for 4 h in the NK cytotoxicity assay.
In Vitro chemotaxis assay
Nucleopore blind well chemotaxis chambers with a lower well 
volume of 200  μL were used. A maximum volume of 200  μL 
medium containing RPMI plus 2% FCS was placed in the lower 
wells in the presence or absence of various chemokines. Cells 
(2 × 105) were placed in the upper compartments and incubated 
for 2 h at 37°C in a 5% CO2 incubator separated by polycarbonate 
filters (Nucleopore Polycarbonate 13 mm size 8 UM, Whatman 
International Ltd., Kent, UK). Filters were removed, dehydrated, 
stained with 15% modified Giemsa stain for 7  min, and then 
mounted on glass slides. Cells in 10 high power fields were 
counted and averaged for each sample. Migration index (MI) was 
calculated as the number of cells migrating toward the concen-
tration gradients of chemokines divided by the number of cells 
migrating toward medium only as previously described (22). For 
pretreatment with PTX, NK cells (1 × 106/mL) were either left 
intact or were treated for 2 h at 37°C with 100 ng/mL-activated 
PTX, as previously described (22). Only more than 95% viable 
cells were examined.
Flow cytometric analysis
IL-2-activated NK cells were either left intact or incubated with 
various concentrations of GA, MMF, or DMF for 24  h. The 
cells were washed and incubated in a 96-well plate (v-bottom, 
2 ×  105  cells per well), washed again, and resuspended in PBS 
buffer containing 0.1% sodium azide and 2% fetal bovine serum. 
Cells were first checked for viability with Trypan blue exclusion 
test, and only more than 95% viable cells were used in the assay. 
These viable cells were labeled with antibodies for 45 min in the 
dark at 4°C, washed twice, and examined in the flow cytometer 
(FACSC II, Becton-Dickinson Biosciences, San Jose, CA, USA). 
Markers were set according to the isotype control FITC- or 
PE-conjugated mouse IgG. More than 95% viable NK cells 
were also incubated at 4°C in the dark with FITC-conjugated 
anti-CD107a or FITC-conjugated IgG1 isotype control (Becton-
Dickinson Pharmingen, San Diego, CA, USA). They were washed 
twice and examined in the flow cytometry. Gating was performed 
according to the isotype control. Analysis was done by FlowJo 
(Flow cytometry analysis software, Ashland, OR, USA).
cell lysis and immunoblotting
More than 95% viable NK cells treated with 100 ng, 1 μg, or 10 μg 
GA for 24 h were lysed with ice-cold Non-idet P-40 lysis buffer 
containing 1% Non-idet P-40, 30 mM Tris–HCl, pH 7.4, 150 mM 
NaCl, 10 mM NaF, 1 mM EDTA, 10 mM sodium pyrophosphate, 
1 mM sodium orthovanadate, 1 mM phenylmethyl-sulfonyl fluo-
ride (PMSF), and a protease inhibitor cocktail (Sigma-Aldrich). 
The solutions were centrifuged at 13,000 × g for 15 min at 4°C 
to separate the cell lysates from the supernatants. Total protein 
concentration in the samples was determined using Bio-Rad 
Protein Assay (Bio-Rad, Uppsala, Sweden), and samples with 
20-μg protein were used for each well in the gel. The samples were 
run on SDS-PAGE criterion gels and then electro transferred to 
PVDF-membranes (Millipore, Bedford, MA, USA). The mem-
branes were blocked with 5% skim milk in TBS for 1 h, and then 
incubated overnight at 4°C with 1:250 dilution of polyclonal rab-
bit antihuman CCR10 or 1:8000 dilution of polyclonal rabbit anti-
GADPH (Both from Abcam, Cambridge, UK). The membranes 
were washed four times in TBS-T-buffer, before incubation with 
HRP-conjugated secondary antibody (1:2500) (Bio-Rad) for 1 h 
at room temperature. Binding of antibodies to the target proteins 
was detected by secondary HRP-labeled antibodies and Super 
Signal West Pico Stable Peroxide Solution (Pierce, Rockford, 
IL, USA), using chemiluminescence film and CURIX 60 (Agfa 
HealthCare, Mortsel, Belgium).
Detection of ccl27 (cTacK) and ccl28 
(Mec) by elisa
Natural killer cells (1 ×  106/mL) were incubated with 100  ng, 
1 μg, or 10 μg of GA, or with culture medium as a control for 
24 h at 37°C in 5% CO2 incubator. After incubation, the cells were 
harvested, and the cell suspensions were centrifuged at 1000 g for 
8 min. Supernatants were collected and stored at −80°C until fur-
ther analysis. Levels of chemokine were measured using ELISA 
kits from RayBiotech Inc. (Norcross, GA, USA). Color intensity 
was measured at 450 nm in a BioTek PowerWave XS plate reader. 
The standard curves and concentrations were calculated using 
Gen5 Data Analysis Software (BioTek Instruments, Winooski, 
VT, USA).
Detection of granzyme B by Flow 
cytometric analysis
IL-2-activated NK cells (1 ×  106/mL) were left intact for 24  h. 
Supernatants were collected from these cells and were kept at 
−80°C until use. To detect the expression of Granzyme B (GrB), 
the cells (1 × 106/mL) were incubated with either media alone or 
with 10 μg/mL of GA overnight. In addition, the cells treated as 
above (with or without GA) were preincubated with supernatants 
collected from activated NK cells either alone or with 1 μg/mL 
mouse antihuman CCL27 or mouse antihuman CCL28 (R&D 
systems), and as a control mouse IgG1.
To stain the intracellular GrB, cells were incubated with 
10 μg/mL Brefeldin A (Sigma-Aldrich) for 4 h. They were then 
fixed with 4% paraformaldehyde for 15  min at 4°C and then 
washed twice with SAP buffer (PBS with 0.1% Saponin and 0.05% 
NaN3) before staining intracellularly with either PE-conjugated 
mouse antihuman Granzyme B or isotype control PE-conjugated 
mouse IgG antibody (both from ImmunoTools, Friesoythe, 
Germany) in the dark at 4°C for 45 min. Cells were washed with 
flow cytometric medium and resuspended with PBS in 5-mL tubes 
to perform flow cytometric analysis. Gating was done according 
to the PE-conjugated isotype control antibody. Analysis was done 
by FlowJo (flow cytometry analysis software, Ashland, OR, USA).
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statistical analysis
Significant values were generated using several tests. We used 
one-way ANOVA, two-way ANOVA with Bonferroni post  hoc 
correction, or the Student’s t-test. A P value <0.05 was considered 
to be statistically significant.
resUlTs
ga Upregulates the expression of ccr10 
on the surface of il-2-activated nK cells 
and induces Their chemotaxis Toward  
its ligands
Natural killer cells migrate into inflammatory sites aided by sets of 
chemokine receptors, which direct them toward the chemokines 
present at tumor growth sites. To this end, we investigated the 
expression of CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, 
CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3, CXCR4, 
CXCR5, CXCR6, CXCR7, and CX3CR1 on the surface of IL-2-
activated NK cells after 24 h incubation with 1 or 10 μg/mL of 
GA. Only more than 90% viable cells as determined by Trypan 
blue exclusion test were used in this and subsequent assays. The 
reasons for choosing activated NK cells are due to the fact that 
at, inflammatory sites such as the tumor microenvironment, 
inflammatory molecules including cytokines and chemokines are 
released, which activate NK cells. In addition, activated NK cells 
migrate toward sites of inflammation much more efficiently than 
non-activated cells [reviewed in Ref. (12)].
From all the chemokine receptors examined, GA upregulated 
the expression of CCR1 and CCR10 on the surface of activated 
NK cells (Figure 1A). Also shown are histograms where CCR10 
is expressed on activated NK cells after incubating overnight with 
10 μg/mL of GA (Figure 1B). We focused the rest of this work on 
the expression of CCR10, since another drug used for treating 
MS patients, namely DMF also upregulates similar expression 
(also see Figure 4). To confirm the upregulation of CCR10 after 
GA stimulation, we performed immunoblot analysis. Results in 
Figure 1C demonstrate that overnight incubation with 0.1, 1, or 
10 μg/mL of GA induced the expression of this receptor on acti-
vated NK cells, despite the fact that flow cytometric analysis did not 
show increase in expression of this receptor after incubation with 
1 μg/mL of GA (Figure 1A).
Consequently, we examined the chemotaxis of activated NK 
cells treated for 24 h with 10 μg/mL GA toward various concen-
trations (ranging from 1 to 1000 ng/mL) of CCL27 and CCL28, 
the ligands for CCR10. Cells untreated with GA migrated with 
low intensity toward high concentrations of CCL27 (100 and 
1000 ng/mL) and CCL28 (10 and 100 ng/mL), which could be 
due to the low number of CCR10 positive NK cells. However, cells 
treated with GA for 24 h migrated toward much lower concen-
trations of CCL27 and CCL28 (Figure 1D). When compared to 
untreated cells, the migration of cells toward the lower concentra-
tions of these chemokines was enhanced by twofold to fivefold 
after treatment with GA, an enhancement that was statistically 
significant (Figure 1D). As a control, we also observed that these 
cells migrated toward the concentration gradients of CCL3, one 
of the ligands for CCR1 after treatment with GA (Figure 1D), 
which is corroborated with increased CCR1 expression on the 
surface of these cells after similar treatment.
Pertussis Toxin inhibits the chemotaxis  
of nK cells
We also investigated whether G proteins might be involved in 
mediating the chemotactic response. Consequently, activated 
NK cells were either left intact or were pretreated with PTX for 
2 h, which intoxicates and inhibits the function of Gi/Go (22). As 
shown in Figure 2A, NK cells migrated toward 10 ng/mL CCL27 
after preincubating for 24 h with 10 μg/mL GA (P <  0.001, as 
compared to the control). This effect was inhibited after prein-
cubating NK cells with PTX (P <  0.04). Similarly, 1  ng/mL of 
CCL28 induced the chemotaxis of NK cells pretreated overnight 
with GA (P < 0.04, as compared to the control), and this activity 
was abrogated upon pretreating the cells with PTX (P <  0.05, 
Figure 2B).
ga enhances nK cell lysis of Tumor 
cells: inhibition by anti-ccr10 antibody
To evaluate whether GA might induce activities other than 
chemotaxis in NK cells, we performed the cytotoxicity assay. 
Results shown in Figure  3 demonstrate that incubating NK 
cells overnight with 10  μg/mL of this drug increased acti-
vated NK cell lysis of K562 cells (Figure  3A), or RAJI cells 
(Figure 3B). Because GA upregulates the expression of CCR10 
on the surface of NK cells, we sought to demonstrate whether 
such expression might influence the cytolytic activity of these 
cells. NK cells either untreated or incubated with 10 μg/mL 
anti-CCR10, or as a control with isotype control IgG antibody, 
were examined for their ability to lyse tumor target cells in the 
NK cytotoxicity assay. We observed that anti-CCR10, and not 
the isotype control IgG, tended to inhibit NK cell lysis induced 
by GA of K562 (Figure  3A), but significantly inhibited lysis 
of RAJI cells (P <  0.05, comparing killing in the presence of 
anti-CCR10 to isotype control IgG, Figure 3B). Of note, cells 
treated overnight with GA and then incubated with isotype 
control IgG antibody also lysed K562 cells (Figure 2A) or RAJI 
cells (Figure 2B), but this did not reach statistical significance 
when compared to untreated cells incubated with the isotype 
control antibody.
il-2-activated nK cells secrete ccl27 
and ccl28
Because anti-CCR10 inhibited GA-induced NK cell cytotoxic-
ity, we entertained various possibilities to explain such activity. 
First, we sought to determine whether GA might induce the 
release of CCL27 or CCL28 from activated NK cells, and that 
these chemokines might facilitate NK cell cytolytic activity by 
binding CCR10. Our results demonstrate that IL-2-activated NK 
cells released an average of 280 pg/mL of CCL27 (Figure S2A in 
Supplementary Material), or 500 pg/mL CCL28 (Figure S2B in 
Supplementary Material). However, addition of various concen-
trations ranging from 0.1 to 10 μg/mL of GA to IL-2-activated NK 
cells did not significantly affect the levels of these chemokines, 
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FigUre 1 | ga upregulates the expression of ccr10 on the surface of nK cells. (a) NK cells (1 × 106/mL) were preincubated overnight with either media 
(C = control) or with 1 or 10 μg/mL of GA. The cells were washed and the expression of CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, 
CXCR2, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7, and CX3CR1 was determined by flow cytometric analysis. Mean ± SEM of three experiments. P values 
were determined using Student’s t-test. (B) Representative experiment showing the expression of CCR10 on the surface of IL-2-activated NK cells after incubating 
with media alone (control) or 10 μg/mL of GA. Gating was done according to the PE-conjugated isotype control antibody. The right panel shows an overlay 
combined results of the first two panels. (c) Immunoblot analysis showing the expression of CCR10 after 24-h pretreatment with media (control) or with 0.1, 1, or 
10 μg/mL of GA. The expression of housekeeping GAPDH protein is also shown. Numbers to the left represent the molecular weights. (D) NK cells migrate toward 
the concentration gradients of CCR10 or CCR1 ligands. Various concentrations ranging between 1 and 1000 ng/mL of CCL3, CCL27, or CCL28 were placed in the 
lower wells of Boyden chambers, whereas 1 × 105 NK cells either untreated (black columns), or pretreated for 24 h with 10 μg/mL of GA (gray columns), were 
placed in the upper wells. Two hours later, the filters were collected, the cells fixed, and then stained with modified Giemsa stain. Migration index was calculated as 
the number of cells migrating in the presence of the chemokine divided by the number of cells migrating in its absence (C = control). A comparison of migration 
toward CCL3, CCL27, and CCL28 among untreated NK cells (black columns) and GA-treated cells (gray columns) was performed using two-way ANOVA test of six 
experiments.
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although a trend in increased release of CCL28 was noted after 
pretreatment with 10 μg/mL GA (Figure S2 in Supplementary 
Material).
Next, we examined whether GA or a combination of GA with 
CCL27 or CCL28 might induce the expression of CD107a on 
the surface of activated NK cells. Histograms of flow cytometric 
analysis showed a trend of increased CD107a expression after 
incubating the cells with GA, CCL27, or CCL28 (Figure S2C in 
Supplementary Material, left). Combining GA with CCL27 or 
CCL28 did not augment such expression when compared to cells 
incubated with GA alone (Figure S2C in Supplementary Material, 
right). When three or more experiments were performed, the 
trend of increased expression of CD107a was also noticed after 
incubating the cells with GA, CCL27, or CCL28. However, 
such enhancement did not reach significant levels after treating 
the cells with GA, any of the two chemokines, or GA plus the 
chemokines (Figure S2D in Supplementary Material).
ga or supernatants collected from il-2-
activated nK cells induce the expression 
of granzyme B in nK cells: inhibition by 
anti-ccl28
To further investigate the plausible mechanisms of CCR10/
chemokines axis, we measured the expression of Granzyme B in 
activated NK cells. For this, NK cells were either incubated with 
xednI
noitargi
M
xednI
noitargi
M
<0.001 <0.04
No PTX                                         PTX
<0.04 <0.05
No PTX                                             PTX
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FigUre 2 | Pretreatment with pertussis toxin (PTX) inhibits ga activity. (a) Migration of cells either left untreated (C = control) or pretreated overnight with 
10 μg/mL of GA toward 10 ng/mL CCL27. Before the assay, these cells were either left intact (left columns) or intoxicated with 100 ng/mL of PTX for 2 h (right 
columns). (B) Migration of cells either untreated (C = control) or pretreated overnight with 10 μg/mL of GA toward 1 ng/mL CCL28. Before the assay, these cells 
were either left intact (left columns) or intoxicated with 100 ng/mL of PTX for 2 h (right columns). P values comparing the migration of cells toward chemokines, and 
its inhibition by pretreatment with PTX, are determined by two-way ANOVA test of six different experiments. C = control. C+ chemokine = untreated cells migrating 
toward the chemokine. GA = cells treated with GA overnight and migrated toward media only (no chemokine). GA+ chemokine = cells treated with GA overnight 
and then migrated toward the chemokine.
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media alone or with 10 μg/mL of GA overnight, and the expres-
sion of Granzyme (GrB) was detected by flow cytometric analysis. 
Such treatment increased the percentages of cells expressing GrB 
from 6 to about 30% after pretreatment with the drug (Figure S3 
in Supplementary Material). Supernatants collected from acti-
vated NK cells, when added to NK cells, also increased such 
expression to about 12%. The enhancement of GrB expression by 
the supernatants was lowered by pretreatment with anti-CCL28 
to about 6%, but not with anti-CCL27, whereas the isotype 
control for the anti-CCL27 and anti-CCL28 also did not affect 
the activity of the supernatants (Figure S3 in Supplementary 
Material, upper panels). Addition of the supernatants to GA did 
not result in any synergy among their activities. However, anti-
CCL28, and to a lesser extent anti-CCL27, reduced the effect of 
GA on GrB expression (Figure S3 in Supplementary Material, 
lower panels).
DMF or MMF also Upregulates the 
expression of ccr10 on the surface  
of il-2-activated nK cells and induces  
Their chemotaxis
To determine whether other drugs or metabolites used to treat 
or have potential for treating MS or cancer patients might affect 
the expression of CCR10 on NK cells similar to GA, we inves-
tigated the effects of various drugs. We observed that none of 
the concentrations of vitamin D3, its metabolite Calcipotriol, or 
FTY720 upregulated the expression of CCR10 on the surface of 
activated NK cells (not shown). In contrast, two different concen-
trations of MMF (1 and 100 μM) or the 100 μM concentration 
of DMF significantly upregulated the expression of CCR10 on 
the surfaces of NK cells (Figure 4A). MMF and the drug DMF 
also upregulated the expression of CXCR3, but not any other 
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FigUre 3 | anti-ccr10 inhibits nK cell lysis of tumor target cells. (a) NK cells were either left untreated (black columns) or incubated with 10 μg/mL of GA 
overnight (gray columns). Before the assay the cells were incubated for 45 min with isotype control IgG antibody or with 10 μg/mL of anti-CCR10, washed, and then 
mixed with Calcein-AM-labeled K562 cells in the 4-h NK cytotoxicity assay. (B) This is similar to (a) except that RAJI tumor cells were used as targets instead of 
K562 cells. Mean ± SEM of four separate experiments.
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chemokine receptor examined (Figure 4A). Histograms of one 
representative experiment showed that 1 and 100 μM of MMF 
or 100 μM of DMF upregulated the expression of CCR10 on the 
surface of human IL-2-activated NK cells when compared to 
cells unstimulated with the drugs (Figure  4B). To corroborate 
the expression of CCR10 with functional activity, we performed 
the chemotaxis assay. Treatment of NK cells with MMF for 24 h 
enhanced their chemotaxis toward CCL27, CCL28, and CXCL10, 
the ligand for CXCR3 (Figure 4C). These results correlated well 
with increased expression of CCR10 and CXCR3 on NK cells after 
incubation with 1 or 100 μM MMF. Surprisingly, pretreatment of 
IL-2-activated NK cells with DMF did not increase their chemo-
taxis toward CCL27. However, their chemotaxis was increased 
toward 1 μg/mL of CCL28 or CXCL10 after overnight incubation 
with 100 μM DMF (Figure 4D).
anti-ccr10 inhibits MMF or DMF-induced 
nK cell lysis of Tumor Target cells
We recently reported that MMF enhanced freshly isolated NK 
cell lysis of tumor cells (20). Because of the differences in the 
expression of NK cytotoxicity receptors among naive vs. activated 
NK cells, we sought to investigate whether MMF or DMF might 
enhance activated NK cell lysis of tumor cells. Pretreatment with 
either MMF or DMF enhanced IL-2-activated NK cell killing of 
K562 tumor cells (Figure 5A). However, only pretreatment with 
MMF, and not DMF, augmented activated NK cell lysis of the B 
cell lymphoma RAJI cells (Figure 5B). These results mirrored our 
recent findings showing that MMF, and not DMF, increased lysis 
of naive NK cells against RAJI cells (20).
Next, we asked whether CCR10 might play a role in MMF or 
DMF augmentation of NK cell cytotoxicity. Similar to its effect on 
GA-enhanced NK cell cytotoxicity, incubating activated NK cells 
with anti-CCR10 for 45 min abrogated the cytotoxicity induced 
by MMF or DMF against K562 cells (Figure  5A) or MMF-
enhanced activated NK cell cytotoxicity against RAJI tumor cells 
(Figure 5B). This effect is not related to a general toxic effect of 
anti-CCR10 antibody as more than 95% of the cells were viable 
after treatment for 45 min with the antibodies.
DiscUssiOn
Natural killer cells stand at the cross road among treatment of 
autoimmune diseases and immunodeficient diseases. In auto-
immune diseases, the best protocol is to suppress the immune 
system, which is achieved by immunosuppressive drugs. On 
the other hand, in immunodeficient diseases, such as cancer or 
AIDS, the immune system must be activated to fight cancer cells 
or virally infected cells, respectively. From a first look, it appears 
that these methods of treatment are contradictory to each other, 
i.e., immunosuppression vs. immunostimulation. However, NK 
cells can be used as a therapeutic modality for both autoimmune 
diseases and cancer (23). Although there are more than 600 NCI 
approved clinical trials using NK cells (http://www.cancer.gov/
search/results) to treat various forms of cancer, investigators are 
faced with the problems of targeting these highly antitumor effec-
tors toward the sites of tumor growth.
Given the fact that NK cells can kill tumors, several strategies 
for the therapeutic use of NK cells have been proposed and tried 
in a clinical context. Cytokines have been used in the treatment of 
some human cancers and, in some instances, the mechanisms of 
action are through direct or indirect activation of NK cells (24). 
NK cell differentiation and activation is affected by cytokines 
such as IL-2, IL-12, IL-15, IL-18, IL-21, and IFNs. Several clinical 
trials have assessed the effects of IL-2 administration on activa-
tion and expansion of NK cells in patients with cancer (25). Apart 
from specific cytokines and/or growth factors, broad activators of 
immune function that are used in cancer treatment may also act 
20
15
10
5
0
0
5
1 0
1 5 MMF-treated DMF-treated
<0.05
<0.05
<0.01
<0.01
<0.01
<0.01
C     1    10   100  1000         1    10  100  1000         1     10   100  1000
CCL27                        CCL28                      CXCL10
M
ig
ra
o
n 
In
de
xxednI noitargi
M
0.001   0.05
slleC evitisoP 
%
A C
0
5
1 0
1 5
C     1    10   100  1000         1   10  100  1000           1    10   100  1000
CCL27                        CCL28                      CXCL10
Iso IgG
Control (no 
treatment)
Iso IgG
1 µM MMF 100 µM MMF
Iso IgG
Iso IgG
100 µM DMF
Control (no 
treatment)
1 µM MMF
100 µM MMF
100 µM DMF
sreb
mu
N lleC
CCR10Mean Fluorescence Intensity
B
C D
CCR1 CCR9CCR8CCR7CCR6CCR5CCR4CCR3CCR2
CCR10 CX3CR1CXCR7CXCR6CXCR5CXCR4CXCR3CXCR2CXCR1
8
6
4
2
0
4
3
2
1
0
20
15
10
5
0
4
3
2
1
0
8
6
4
2
0
2
1.5
1
0.5
0
4
3
2
1
0
20
15
10
5
0
C    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMF
C    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMFC    1   100 DMF
14
10
6
2
0
40
30
20
10
0
4
3
2
1
0
80
60
40
20
0
20
15
10
5
0
2
1.5
1
0.5
0
8
6
4
2
0
2
1.5
1
0.5
0
4
3
2
1
0
0.001 0.05
FigUre 4 | MMF or DMF upregulates the expression of ccr10 and cXcr3 on nK cells and induces their chemotaxis toward the corresponding 
chemokines. (a) NK cells (1 × 106/mL) were preincubated overnight with either media (C = control) or with two different concentrations of MMF (1 and 100 μM) or 
with 100 μM DMF. The cells were washed, and the expression of CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR2, CXCR2, 
CXCR3, CXCR4, CXCR5, CXCR6, CXCR7, and CX3CR1 was determined by flow cytometric analysis. P values were determined using Student’s t-test of three 
experiments comparing the percentages of CCR10+ or CXCR3+ NK cells after treatment with MMF or DMF to the controls. (B) Representative experiment showing 
the expression of CCR10 on the surface of IL-2-activated NK cells after incubating with media alone (control), 1 or 100 μM MMF, or 100 μM DMF. Gating was done 
according to the PE-conjugated isotype control antibody. The right panel shows an overlay combined results of the first four panels. (c) NK cells migrate toward the 
concentration gradients of CCR10 or CXCR3 ligands. Various concentrations ranging between 1 and 1000 ng/mL of CCL27, CCL28, or CXCL10 were placed in the 
lower wells of Boyden chambers, whereas 1 × 105 NK cells either untreated (C = control) or pretreated with 100 μM MMF were placed in the upper chambers. Two 
hours later, the filters were collected, the cells fixed, and then stained with modified Giemsa stain. Migration index was calculated as the number of cells migrating in 
the presence of the chemokine divided by the number of cells migrating in its absence (C = control). A comparison of migration toward CCL27, CCL28, or CCL3 
among untreated NK cells (black columns) and MMF-treated cells was performed using two-way ANOVA test of six experiments. (D) This is similar to (c), except 
that 100 μM DMF was used instead of MMF.
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on NK cells (25). Similarly, NK cells may have a role in the clinical 
efficacy of Mycobacterium bovis bacillus Calmette–Guérin (BCG) 
treatment of bladder cancer (26), indicating that mediators, which 
activate endogenous NK cells, can induce immune-mediated 
control of cancer. The potential efficacy of NK cells in treating 
various forms of cancer has been extensively reviewed (27–33).
CCL27 (CTACK) is expressed in epidermal keratinocytes and 
is responsible for attracting CCR10+ T cells into the skin (34, 
35). On the other hand, CCL28 is expressed by epithelial cells 
of mucosal sites (36–38) and is upregulated in inflamed tissues 
such as colon, duodenal mucosa, lungs, and liver ducts (39–41). 
Further, treatment of Crohn’s disease patients resulted in reduced 
expression of CCR10 corroborated with reduced inflammation in 
those patients [reviewed in Ref. (42)].
Intratumoral administration of CCR10 as well as other 
chemokine-expressing adenoviral vector into tumor-bearing ani-
mals resulted in the recruitment and activation of T cells at sites 
of tumor growth (43). Similarly, transfecting CCL27 into ovarian 
carcinoma cells resulted in reduced tumor growth by antitumor 
immune responses (44). Human keratinocyte-derived skin 
tumors can evade T cells antitumor activity by downregulating 
the expression of CCR10. Further, in vivo work demonstrated that 
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FigUre 5 | MMF or DMF augments activated nK cell cytotoxicity against tumor cells: inhibition by anti-ccr10 antibody. (a) NK cells were either left 
intact (black columns) or incubated with 100 μM MMF or DMF overnight (gray columns), washed, and then incubated with K562 cells. (B) is similar to (a) except 
that RAJI cells were used in the NK cytotoxicity assay. For treatment with anti-CCR10, the cells were washed and incubated with either 10 μg/mL of anti-CCR10 or 
isotype control IgG antibody for 45 min before incubating with the target cells. Percent cytotoxicity was then measured, and significant values as compared to the 
control in each treatment are shown on top of the columns. Significance of cytotoxicity in the presence of anti-CCR10 was compared to the cytotoxicity in the 
presence of isotype control IgG antibody. Mean ± SEM of four experiments.
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neutralization of CCL27 decreased leukocyte recruitment toward 
cutaneous tumor sites, resulting in enhanced tumor growth (45).
In contrast, it was observed that overexpression of CCR10 and 
CCR7 resulted in severe outcome of human cutaneous melanoma 
growth, as determined by high risk of relapse and death of patients 
(46). Along these lines, Kai et al. (47) observed that CCR10 and 
CCL27 were strongly expressed in human cutaneous squamous 
cell carcinoma, which is advantageous for tumor cell survival 
and proliferation. Further, hypoxic tumor cells released CCL28 
recruiting CCR10+ Treg cells, which promote tumor growth and 
angiogenesis, an activity that was abrogated by anti-CCL28 (48).
To this end, we observed that GA upregulates the expression of 
CCR10 on the surface of human NK cells. This activity corrobo-
rated with enhanced migration of these cells toward the concen-
tration gradients of CCL27 and CCL28, the ligands for CCR10. 
PTX inhibited the chemotactic effects induced by chemokines, 
suggesting that G protein-coupled receptors (GPCRs), and in 
particular Gi/o, are involved. PTX also inhibited the cytolytic 
activity of NK cells induced by GA against tumor cells. Because 
chemokines bind GPCRs, we entertained the possibility that 
CCR10 could be involved in mediating NK cell cytotoxicity. We 
observed that anti-CCR10 reduced NK cell lysis of tumor target 
cells. Although the reasons behind such enigmatic effect are not 
clear, it is plausible that a complex interaction takes place resulting 
in activating the lytic potential of NK cells. It is conceivable that 
CCR10 upregulated by GA might interact with the CCR10 ligands 
such as CCL27 and CCL28 secreted by activated NK cells. Such 
binding may result in inducing intracellular signaling molecules 
that may mediate the cytolytic activity of NK cells. Hence, anti-
CCR10 or PTX might interfere with such interaction resulting 
in inhibiting NK cells mediating lysis of tumor cells. Our results 
did not detect any increases in the levels of CCL27 or CCL28 
secreted by NK cells after stimulation with GA. Neither there was 
a synergy among GA and these chemokines in the upregulation of 
CD107a on the surface of these cells. This molecule is considered 
an activation marker for NK cell-mediated lysis of tumor cells, and 
its expression is increased after incubating resting NK cells with 
MMF (20). Further analysis showed that supernatants collected 
from activated NK cells increased the percentages of Granzyme B 
positive cells, and that such activity was inhibited by pretreatment 
with anti-CCL28 indicating that CCL28 secreted by activated NK 
cells might bind CCR10 and consequently, upregulate the expres-
sion of lytic molecules on higher numbers of NK cells. GA also 
increased the percentages of Granzyme B positive NK cells, and 
this effect was reduced by anti-CCL28. Albeit not examined, it is 
plausible that GA might also utilize CCL28, perhaps to increase 
the expression of GrB. Although we have not seen a significant 
increase of CCL28 release after pretreatment with GA, we noted 
a trend of such enhancement.
Similar to GA, MMF and DMF also upregulated the expres-
sion of CCR10 on the surface of activated NK cells. Further, 
these chemicals enhanced activated NK cell lysis of tumor target 
cells. Similar to GA effect, such enhancement of cytotoxicity 
was abrogated by pretreatment with anti-CCR10. More work is 
needed to explore in details such an exciting possibility involving 
chemokines/chemokine receptors axis in mediating not only the 
migration of NK cells but also other activities such as cytotoxicity.
We consider the most important aspect of this work is the find-
ing that drugs for MS such as GA and DMF as well as MMF upreg-
ulate the expression of CCR10 on the surface of IL-2-activated 
NK cells. Such finding might have potential relevance for treating 
cancer, particularly those tumors that secrete chemokines, which 
bind CCR10, including malignant melanomas and squamous cell 
carcinomas, which secrete CCL27 (47, 49), or colorectal cancer 
cells that secrete CCL28 (50). This is particularly relevant when 
one considers that there is an estimated 2–5 × 109 NK cells in 5 L of 
blood. A 1% of this NK cell number represents a subset of NK cells 
that expresses CCR10 (an estimated number of 20–50 × 108/5 L of 
blood). A 10% increase after treatment with the drugs described 
in this manuscript suggests that the number of CCR10+ NK cells 
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might be increased to about 200–500 × 108/5 L of blood; a sub-
stantial number of killer cells that may potentially inhibit tumor 
growth. Our next step is to examine in tumor-bearing animals 
whether these CCR10+-activated killer cells may migrate into the 
sites of colorectal cancers or melanomas after pretreatment with 
GA, MMF, or DMF. A number of cancers are, at present, incur-
able. For others, chemotherapy is only partially effective, and a 
significant proportion of patients relapse following treatment. 
Some hematological malignancies are treatable by hematopoietic 
stem cell transplantation (HSCT), but fewer than 30% of patients 
requiring HSCT have a suitable donor. NK cells possess the ability 
to spontaneously lyse certain target cells, including tumor cells. 
The major issue that faced investigators in this field is the inability 
of NK cells to migrate toward sites of tumor growth. This, despite 
the existence of more than 600 approved clinical trials using NK 
cells to treat various cancers. Our present work may provide a 
novel approach of harnessing activated NK cells in vitro for the 
purpose of administering into cancer patients. We propose that 
these cells can be harnessed in vitro with drugs such as GA, DMF 
(or MMF). These drugs perform two important functions for 
these cells; first, they increased their cytotoxicity against tumor 
cells, and second, they upregulate the expression of CCR10 on 
their surfaces. Consequently, NK cells can be targeted toward the 
growth of tumor cells that secrete CCL27 and CCL28.
cOnclUsiOn
We previously described the effects of GA on chemokine 
receptor expression in an MS patient receiving this drug (51). 
However, this is the first demonstration that GA, DMF, and MMF 
upregulate the expression of an important chemokine receptor, 
i.e., CCR10, on the surface of activated NK cells. Such activity 
might have important implications in NK cell immunotherapy. 
Because immunotherapy using NK cells suffers from the inability 
of these cells to migrate into tumor stroma, it is now feasible to 
direct these cells toward sites of tumor growth, particularly those 
secreting CCL27 and CCL28. Hence, we suggest the feasibility of 
using such approach to treat cutaneous squamous cell carcinomas 
and squamous melanoma, as well as colorectal cancer.
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FigUre s1 | expression of cD56 molecule on the surface of il-2-activated 
nK cells. (a) Activated NK cells were labeled with either mouse FITC-conjugated 
isotype IgG or mouse FITC-conjugated anti-CD3 antibody. (B) Activated NK 
cells labeled with mouse PE-conjugated isotype IgG or mouse PE-conjugated 
anti-CD56 antibody. (c) Activated NK cells labeled with both FITC-conjugated 
anti-CD3 antibody and PE-conjugated anti-CD56 and examined in the flow cytom-
etry. One of the four representative experiments was performed.
FigUre s2 | il-2-activated nK cells release ccl27 and ccl28 and 
express cD107a. (a) NK cells were either left intact or were incubated for 
24 h with 0.1, 1 or 10 μg/mL GA. Supernatants were collected, and the levels 
of CCL27 were measured. (B) CCL28 levels were evaluated using ELISA assay. 
(c) A representative experiment showing histograms for the expression of CD107a 
after incubating overnight with 10 μg/mL GA, 10  ng/mL CCL27, or 10  ng/mL 
CCL28 (left panel), or 10 μg/mL GA either alone or in combination with 10 ng/mL 
CCL27 or 10  ng/mL CCL28 (right panel). (D) Activated NK cells (1 ×  106/mL) 
were either untreated (–) or incubated overnight with 10 μg/mL GA (GA), 100 ng/
mL CCL27, 100 ng/mL CCL28, or a combination of 10 μg/mL GA with 100 ng/
mL CCL27 (GA + CCL27), or 100 ng/mL CCL28 (GA + CCL28). The cells were 
washed, and the expression of CD107a was evaluated by flow cytometric analysis. 
Mean ± SEM of values from three different donors. The binding of isotype control 
antibody is also shown.
FigUre s3 | ga or supernatants collected from il-2-activated nK cells 
increase the percentages of nK cells expressing granzyme B. IL-2-
activated NK cells were incubated for 24 h with either media alone or with 10 μg/mL 
GA. In both treatments, the cells were incubated with supernatants collected 
from IL-2-activated NK cells. In other cultures, the cells were pretreated with the 
supernatants in the presence of 1 μg/mL mouse IgG isotype control for anti-CCL27 
and anti-CCL28, or with 1 μg/mL of neutralizing mouse anti-CCL27 or mouse 
anti-CCL28. Upper panels show expression of Granzyme B in the absence of 
GA, whereas lower panels show expression of the same molecule in the presence 
of 10  μg/mL GA. One of the two representative experiments was performed. 
Percentages of positive cells are shown between brackets.
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